NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

Novo Ventures has led a $55 million series B round for NodThera, a trans-Atlantic biotech operating in an area ripe for takeouts -- the inflammasome.

The biotech's lead program targets NLRP3, a target explored by three biotechs that have been acquired in the last three years. For the two deals with disclosed terms, each of the biotechs received at least $300 million up front, and each was eligible for more than $1 billion in milestones. ...